{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:54:14Z","timestamp":1791107654882,"version":"4.1.0"},"reference-count":55,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2013,5,31]],"date-time":"2013-05-31T00:00:00Z","timestamp":1369958400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0065036","type":"journal-article","created":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:54:05Z","timestamp":1370048045000},"page":"e65036","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":28,"title":["Meningococcal Serogroup A, C, W135 and Y Conjugated Vaccine: A Cost-Effectiveness Analysis in the Netherlands"],"prefix":"10.1371","volume":"8","author":[{"given":"Hiltsje","family":"Hepkema","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen B.","family":"Pouwels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arie","family":"van der Ende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjalke A.","family":"Westra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten J.","family":"Postma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,5,31]]},"reference":[{"key":"ref1","first-page":"521","article-title":"Meningococcal vaccines: WHO position paper, November 2011","volume":"86","year":"2011","journal-title":"Wkly Epidemiol Rec"},{"key":"ref2","unstructured":"World Health Organization, SAGE Working Group (2011) Background paper on meningococcal vaccines. Available: http:\/\/www.who.int\/immunization\/sage\/1_mening_background_document_v5_3__apr_2011.pdf<\/ext-link>. Accessed 22 June 2012."},{"key":"ref3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/00365540110080179","article-title":"Sequelae after bacterial meningitis in childhood","volume":"34","author":"R Oostenbrink","year":"2002","journal-title":"Scand J Infect Dis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1017\/S0950268800057472","article-title":"Patient and strain characteristics in relation to the outcome of meningococcal disease: A multivariate analysis","volume":"112","author":"RJ Scholten","year":"1994","journal-title":"Epidemiol Infect"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/01.inf.0000195594.41449.c6","article-title":"Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands","volume":"25","author":"SC De Greeff","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/527401","article-title":"Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity","volume":"197","author":"MC Maiden","year":"2008","journal-title":"J Infect Dis"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1586\/erv.09.48","article-title":"Meningococcal vaccines and herd immunity: Lessons learned from serogroup C conjugate vaccination programs","volume":"8","author":"CL Trotter","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"ref8","unstructured":"De Voer RM (2010) Meningococcal C specific immune responses: Immunity in an era of immunization with vaccine. Utrecht: Utrecht University."},{"key":"ref9","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: A systematic review and meta-analysis","volume":"10","author":"H Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"e12144","DOI":"10.1371\/journal.pone.0012144","article-title":"Immunity against Neisseria meningitides serogroup C in the Dutch population before and after introduction of the meningococcal C conjugate vaccine","volume":"5","author":"RM De Voer","year":"2010","journal-title":"PloS One"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1128\/CVI.05655-11","article-title":"Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitides in England a decade after vaccine introduction","volume":"19","author":"DA Ishola Jr","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2334-12-35","article-title":"Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? Experience from the Netherlands","volume":"12","author":"P Kaaijk","year":"2012","journal-title":"BMC Infect Dis"},{"key":"ref13","unstructured":"Ministry of Health Austria (2012) Immunization schedule Austria. Available: http:\/\/www.bmg.gv.at\/cms\/home\/attachments\/7\/3\/0\/CH1081\/CMS1286449898381\/impfplan_2012_final,_1.2.2012.pdf<\/ext-link>. Accessed 2012 Jul 19."},{"key":"ref14","unstructured":"World Health Organization (2012) Immunization schedule Switzerland. Available: http:\/\/apps.who.int\/immunization_monitoring\/en\/globalsummary\/ScheduleResult.cfm<\/ext-link>. Accessed 2012 Jul 19."},{"key":"ref15","unstructured":"Netherlands Reference Laboratory for Bacterial Meningitis. Bacterial meningitis in the Netherlands. Annual reports 2007\u20132011. Amsterdam: University of Amsterdam, the Netherlands."},{"key":"ref16","unstructured":"European Medicines Agency (2012) EPAR-summary for the public: Nimenrex (EMA\/CHMP\/136315\/2012). Available: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/002226\/WC500127665.pdf<\/ext-link>. Accessed 2012 Dec 14."},{"key":"ref17","unstructured":"Hakkaart-van Roijen L, Tan SS, Bouwmans CAM (2010) Guidelines for costing research, methods and standardized prices for economic evaluations in health care. Diemen: Health Care Insurance Board."},{"key":"ref18","unstructured":"Statistics Netherlands. Available: http:\/\/statline.cbs.nl<\/ext-link>. Accessed 2012 Nov 15."},{"key":"ref19","unstructured":"European Union invasive bacterial infections surveillance network (2001) Invasive Neisseria meningitides in Europe \u20132001. Available: http:\/\/www.hpa-bioinformatics.org.uk\/euibis\/documents\/2001_meningo.pdf<\/ext-link>. Accessed 2012 Dec 14."},{"key":"ref20","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.vaccine.2004.06.019","article-title":"Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in the Netherlands and its impact on decision-making","volume":"23","author":"R Welte","year":"2004","journal-title":"Vaccine"},{"key":"ref21","unstructured":"Stouthard MEA, Essink-Bot ML, Bonsel GJ, Barendregt JJ, Kramers PGN, et al<\/etal>.. (1997) Disability weights for disease in the Netherlands. Rotterdam: Department of Public Health, Erasmus University, the Netherlands."},{"key":"ref22","unstructured":"Dutch Ministry of Education Culture and Science (2012) Key figures 2007\u20132011. Available: http:\/\/www.government.nl\/documents-and-publications\/reports\/2012\/07\/24\/key-figures-2007-2011.html<\/ext-link>. Accessed 2012 May 16."},{"key":"ref23","unstructured":"College of Health Insurances. Pharmaceutical price meningococcal serogroup ACWY vaccine (Nimenrix\u00ae). Available: http:\/\/www.medicijnkosten.nl\/<\/ext-link>. Accessed 2012 Jul 26."},{"key":"ref24","unstructured":"College of Health Insurances. Pharmaceutical price meningococcal serogroup C vaccine (Neisvac-C\u00ae). Available: http:\/\/www.medicijnkosten.nl\/<\/ext-link>. Accessed 2012 Jul 26."},{"key":"ref25","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.vaccine.2009.10.064","article-title":"A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children","volume":"28","author":"M Knuf","year":"2010","journal-title":"Vaccine"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1016\/j.vaccine.2011.03.009","article-title":"Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, Tichmann-Schumann I, Maurer H, et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix hexa is immunogenic, with an acceptable safety profile in 12\u201323-month-old children","volume":"29","journal-title":"Vaccine"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1016\/j.vaccine.2011.03.043","article-title":"Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial","volume":"29","author":"T Vesikari","year":"2011","journal-title":"Vaccine"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Vesikari T, Forsten A, Boutriau D, Bianco V, van der Wielen M, et al<\/etal>.. (2012) Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers. Hum Vaccin Immunother 8. doi: http:\/\/dx.doi.org\/10.4161\/hv.22166<\/ext-link>.","DOI":"10.4161\/hv.22166"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"B20","DOI":"10.1016\/j.vaccine.2009.04.067","article-title":"Meningococcal C conjugate vaccine: The experience in England and Wales","volume":"27","author":"H Campbell","year":"2009","journal-title":"Vaccine"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1128\/CVI.00529-09","article-title":"Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: Effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity","volume":"17","author":"H Campbell","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"c2509","DOI":"10.1136\/bmj.c2509","article-title":"Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines","volume":"304","author":"MH Rozenbaum","year":"2010","journal-title":"BMJ"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1016\/j.vaccine.2006.02.010","article-title":"Relative efficacy of different immunization schedules for the prevention of serogroup C meningococcal disease: a model-based evaluation","volume":"24","author":"P De Wals","year":"2006","journal-title":"Vaccine"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"LH Harrison","year":"2009","journal-title":"Vaccine"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"B26","DOI":"10.1016\/j.vaccine.2011.12.032","article-title":"The chancing and dynamic epidemiology of meningococcal disease","volume":"Suppl2","author":"SA Halperin","year":"2012","journal-title":"Vaccine 30"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2165\/11535280-000000000-00000","article-title":"Methodological concerns with economic evaluations of meningococcal vaccines","volume":"28","author":"TL Kauf","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"5945","DOI":"10.1016\/j.vaccine.2007.04.070","article-title":"Do we fully understand the economic value of vaccines?","volume":"25","author":"M Drummond","year":"2007","journal-title":"Vaccine"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1016\/j.vaccine.2005.03.045","article-title":"Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain","volume":"23","author":"A Larrauri","year":"2005","journal-title":"Vaccine"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/oxfordjournals.epirev.a017931","article-title":"Epidemiologic methods in immunization programs","volume":"18","author":"RT Chen","year":"1996","journal-title":"Epidemiol Rev"},{"key":"ref39","first-page":"861","article-title":"Association of meningococcal serogroups with the course of disease in the Netherlands, 1959\u201383","volume":"65","author":"L Spanjaard","year":"1987","journal-title":"Bull World Health Organ"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S1473-3099(06)70584-9","article-title":"No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales","volume":"6","author":"CL Trotter","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"ref41","unstructured":"European Medicines Agency (2013) EPAR-summary for the public: Bexsero (EMA\/755874\/2012). Available: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002333\/human_med_001614.jsp&mid=WC0b01ac058001d124<\/ext-link>. Accessed 2013 Mar 5."},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Pouwels KB, Hak E, van der Ende A, Christensen H, van den Dobbelsteen GPJM, et al<\/etal>.. (2013) Cost-effectiveness of vaccination against meningococcal B among Dutch infants: crucial impact of changes in incidence. Hum Vaccin Immunother 9. doi: http:\/\/dx.doi.org\/10.4161\/hv.23888<\/ext-link>.","DOI":"10.4161\/hv.23888"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomized trials","volume":"381","author":"T Vesikari","year":"2013","journal-title":"Lancet"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Gill CJ (2013) Novel assessment of a novel meningitis B vaccine. Lancet Infect Dis. doi: http:\/\/dx.doi.org\/10.1016\/S1473-3099(13)70037-9<\/ext-link>.","DOI":"10.1016\/S1473-3099(13)70037-9"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1542\/peds.2004-2514","article-title":"Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States","volume":"115","year":"2005","journal-title":"Pediatrics"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/524041","article-title":"Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States","volume":"46","author":"IR Ortega-Sanchez","year":"2008","journal-title":"CID"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1016\/j.vaccine.2007.04.071","article-title":"Vaccinating adolescents against meningococcal disease in Canada: A cost-effectiveness analysis","volume":"25","author":"P De Wals","year":"2007","journal-title":"Vaccine"},{"key":"ref48","first-page":"14","article-title":"Safety of meningococcal group C conjugate vaccines","volume":"26","year":"2000","journal-title":"Current Problems in Pharmacovigilance"},{"key":"ref49","unstructured":"Van Lier EA, Oomen PJ, Giesbers H, Drijfhout IH, de Hoogh PAAM, et al<\/etal>.. (2012) Immunization coverage National Immunization Programme in the Netherlands: Year of report 2012. Report no. 201001001, National Institute of Health and the Environment, Bilthoven, the Netherlands."},{"key":"ref50","unstructured":"Neppelenbroek SE, de Vries M, Greeff SC, Timen A (2002) \u2018da\u2019s goed gedaan? Woordverslag van de landelijke vaccinatiecampagne meningokokken C. ISBN 90\u201372779\u201338-X. 2003. GGD Nederland."},{"key":"ref51","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s10096-008-0535-1","article-title":"Pre-admission clinical course of meningococcal disease and opportunities for the earlier start of appropriate intervention: a prospective epidemiological study on 752 patients in the Netherlands, 2003\u20132005","volume":"27","author":"SC De Greeff","year":"2008","journal-title":"Eur J Clin Microbriol Infect Dis"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1128\/CMR.13.1.144-166.2000","article-title":"Update on meningococcal disease with emphasis on pathogenesis and clinical management","volume":"13","author":"M Van Deuren","year":"2000","journal-title":"Clin Microbiol Rev"},{"key":"ref53","unstructured":"Dutch Healthcare Authority. Medical specialized treatment and its tariffs 2011. Available: http:\/\/www.nza.nl\/137706\/145406\/BR-CU-2015_bijlage_2_med.spec.behandelingen-en-tarieven_2011.xls<\/ext-link>. Accessed 2012 May 28."},{"key":"ref54","unstructured":"Dutch Association of Hospitals. Number of general hospitals to bed numbers. Available: http:\/\/www.nvz-ziekenhuizen.nl\/feiten_en_cijfers\/FAQ#beddenaantal<\/ext-link>. Accessed 2012 May 28."},{"key":"ref55","unstructured":"Kind P, Hardman G, Macran S. (1999) UK population norms for EQ-5D. Discussion paper 172. The University of York Centre for Health Economics. Available: http:\/\/www.york.ac.uk\/inst\/che\/pdf\/DP172.pdf<\/ext-link>. Accessed 2012 Jun 1."}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0065036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T09:04:04Z","timestamp":1540199044000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0065036"}},"subtitle":[],"editor":[{"given":"Ray","family":"Borrow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,5,31]]},"references-count":55,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2013,5,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0065036","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,31]]}}}